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Background. Genital tract (GT) inflammation plays a major role in HIV transmission. We aimed to determine the association
between symptomatic vulvovaginal candidiasis (VVC) and HIV RNA levels in plasma and GTs of HIV-infected women on
highly active antiretroviral therapy (HAART).
Method. Women with VVC on HAART were recruited from a primary healthcare clinic in KwaZulu-Natal Province, South
Africa, between June 2011 and December 2011. VVC was diagnosed clinically, supported by Gram staining and culture of
genital secretions. HIV RNA load was determined by reverse transcription polymerase chain reaction. CD4+ counts were
obtained from patients’ medical records.
Results. Plasma HIV RNA was detected in 42 of 60 (70%) patients on HAART. The mean duration (± standard deviation) on
HAART for these patients was 4.2 (±1.6) months v. 10.7 (±1.4) months for the remaining 18 patients (p<0.0001). Of the 42
women with detectable plasma HIV RNA, 12 (28.6%) had detectable genital HIV RNA. Plasma HIV RNA levels ranged from
2.5 (±0.8) to 4.1 (±0.8) log10 copies/ml. Genital HIV RNA levels ranged from 1.4 to 2.5 (±1.1) log10 copies/ml. The adjusted odds
ratios of plasma HIV RNA levels increased for patients <35 years (p=0.039) and in those with VVC (p=0.008). Detectability
of HIV in genital secretions was significantly increased in patients with a plasma HIV load ≥10 000 copies/ml (p=0.032) and
genital absolute counts of neutrophils >10 cells/5 high microscopic fields (p=0.007).
Conclusion. Given that the majority of women had recently initiated HAART (allowing a high rate of detectable plasma HIV
RNA), there was insufficient evidence to conclude that VVC was predictive of high plasma HIV RNA levels. It is more likely that
this cohort of immunosuppressed women were prone to develop VVC. Plasma HIV loads and local genital inflammation were
predictors of genital HIV detectability.
S Afr J HIV Med 2014;15(2):57-64. DOI:10.7196/SAJHIVMED.975

Ulcerative and non-ulcerative lower genital
tract infections (LGTIs) are thought to play
a major role in early HIV pathogenesis and
transmission.[1] LGTIs and plasma HIV viral
load (VL) partially explain HIV shedding in
the female genital tract (GT).[1,2] Some studies have suggested
that changes in the normal microbial flora of the female GT
contribute to viral shedding.[1-3]
Conditions associated with genital inflammation, particularly
genital ulcers, have been associated with HIV shedding in the
GT.[4,5] While the association between non-ulcerative LGTIs
such as bacterial vaginosis (BV) and GT HIV shedding has
been well established,[6,7] current studies have shown a less welldefined relationship between vulvovaginal candidiasis (VVC)

and HIV shedding. In addition to BV that is not an established
sexually transmitted infection (STI), vaginitis , an STI caused
by Trichomonas vaginalis, has also been shown to increase
the risk of HIV acquisition among women,[8,9] and sexual and
perinatal HIV transmission.
Data on the effect of highly active antiretroviral therapy
(HAART) on vaginal infections among HIV-infected women
are limited. Factors such as changes in vaginal immunological
cell populations, cellular activation and cytokine production
have been reported to alter susceptibility or response to genital
infections.[10-13] However, it remains unclear whether chemokines
and cytokines interfere with the activity of polymorphonuclear
neutrophil (PMN) cells and macrophages in the mucosa, or
whether they facilitate the development of VVC.
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Objective
Our objective was to determine the association between symptomatic
VVC and HIV RNA levels in the plasma and GTs of HIV-infected
women on HAART. We hypothesised that in HIV-infected women, the
presence of symptomatic VVC would affect local HIV shedding, but not
systemic levels.

Methods

Study population
For this cross-sectional study, consecutive adult (≥18 years) women (all
HIV-infected) attending Umlazi D clinic, a primary healthcare facility
in KwaZulu-Natal (KZN) Province, South Africa, between June 2011
and December 2011 were enrolled after giving informed consent. Data
on current symptoms suggestive of LGTIs were obtained by means of
a standard questionnaire. Patients on HAART were defined as those
receiving treatment with ≥2 nucleoside reverse transcriptase inhibitors
(NRTIs) and ≥1 protease inhibitor (PI) or non-nucleoside reverse
transcriptase inhibitor (NNRTI).
A physical examination was performed by the attending medical
practitioner and signs of LGTIs were noted. Sixty paired plasma and
cervicovaginal samples were collected from HIV-infected women
receiving HAART. Patients aged <18 years and those who were
menstruating or had visible blood contamination of genital samples
were excluded from the study.
The study was approved by the Biomedical Research Ethics Com
mittee of the University of KZN (Ref. BE 224/11). Consent forms
were signed by all participants and confidentiality was maintained
throughout the study.

Collection and processing of cervicovaginal fluid
A vaginal tampon (8 Ks), Tampax Regular® (Compak), was inserted
into the vagina, left in situ for 3 minutes, and then placed in a sterile
container containing 10 ml of phosphate-buffered saline (Oxoid Ltd
Basingstoke, UK) (pH 6.9). Samples were stored at 4oC for 4 hours prior
to transport to the laboratory. Vaginal fluid was expressed using an
autoclaved wooden tongue depressor and filtered through 0.22 μm
Costar Spin-X cellulose acetate filter membranes (Sigma). The filtered
soluble fraction was aliquoted (in 1 ml cryotubes) and stored at –70oC
until use.

Measurement of absolute PMN cell counts
from lower GT samples
A vaginal swab (Becton Dickinson (BD)) was used to collect cells from
the posterior fornix and to prepare a tissue smear on a glass slide for Gram
staining. Absolute counts of neutrophils were determined by counting the
total number of PMN cells in five randomly selected microscopic fields
under oil immersion (×1 000 magnification) as previously described. The
scores were as follows: score 1: 1 - 10 PMN cells/5 high microscopic fields
(HMFs); score 2: 11 - 20 PMN cells/5 HMFs; score 3: >20 PMN cells/5
HMFs.[14-16]

Diagnostic criteria for symptomatic VVC and
VVC colonisation
The diagnosis of symptomatic VVC was based on a combination of
clinical and laboratory criteria (evidence level III, recommendation
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grade B).[17-19] Symptoms suggestive of VVC included vulval pruritus,
vulval soreness, superficial dyspareunia, and/or non-offensive vaginal
discharge. Signs included vulval erythema, vulval oedema, fissures,
excoriation or thick curdy vaginal discharge.
A vaginal swab (BD) taken from the anterior fornix was directly
plated onto Sabouraud Dextrose agar with chloramphenicol (BBLTM,
BD) and incubated at 29oC for 48 hours to estimate the relative vaginal
fungal burden. The numbers of yeast colonies were recorded as the
number of colonies per plate.[17-19]
In addition to the self-reported symptoms listed above and
observation of signs suggestive of VVC on physical examination, cases
of symptomatic VVC were confirmed if one of the following criteria
was fulfilled (evidence level III, recommendation grade B):[17-19] (i) a
positive Gram-stain preparation with budding yeasts, pseudohyphae,
and/or hyphal forms; and (ii) positive culture with either moderate
(10 - 99 colonies per plate) or heavy (>100 colonies per plate) Candida
growth.
Participants without symptomatic VVC were defined as: (i) patients
whose genital specimens were negative for yeasts, pseudohyphae, and/
or hyphal forms of Candida on microscopy, together with negative
culture; and (ii) patients whose genital specimens were negative for
yeasts, pseudohyphae on microscopy, and/or hyphal forms of Candida
together with light Candida growth (<10 colonies per plate). The latter
was considered to indicate vaginal Candida colonisation rather than
infection.

Definitions of HIV-induced
immunosuppression
As part of the routine management and standard of care in the clinic,
CD4+ T-cell counts were measured in the blood of all HIV-infected
patients. The CD4+ T-cell counts used in this study were obtained
from the past 3 months of measurements in patients’ medical records.
However, for the purpose of this research, HIV RNA was measured
from the plasma and cell-free fraction of vaginal secretions using
Nuclisens Easyq HIV-1 version 2.0 (BioMerieux, France) with a lowest
detection limit of 20 copies/ml.[20-22]
Absolute values of CD4+ T-cell counts (cells/µl) were used to
determine the degree or severity of immunosuppression as per the
World Health Organization immunological staging criteria: severe
immunosuppression (<200/µl); advanced immunosuppression (200
- 349/µl); and mild immunosuppression (350 - 499/µl).[23] HIV VL and
CD4+ counts were used as markers of disease progression.[23-25] For
the purpose of this study, plasma viraemia was classified as follows:
<20 copies/ml (below detectable level of the test used); 20 - 9 999
copies/ml; and ≥10 000 copies/ml. We also log-transformed HIV loads
for improved symmetry and included them in multivariate logistic
regression models as continuous values.

Diagnosis of other LGTIs
For each study participant, clinical symptoms and signs suggestive of
LGTIs were recorded and categorised as absent, mild, moderate or
severe. The diagnosis of BV was made using Nugent’s scores.[15,16] BD
nucleic acid amplification tests (BD Probetec Assays, Sparks) were
performed on all cervical swabs to detect Chlamydia trachomatis
and Neisseria gonorrhoeae. In addition, polymerase chain reaction
amplifications of DNA isolated from vaginal swabs were performed as

Categorical variables were expressed as pro
portions (%), and quantitative (discrete ordinal)
variables were presented as mean (± standard
deviation). For univariate analyses, the χ2 test
was used to compare proportions, while the
R coefficient was computed to analyse the co
rrelations between quantitative variables. Fur
thermore, univariate association between HIV
RNA detectability (in plasma or vagina) and
putative risk indicators was defined by odds
ratios (ORs) with 95% confidence intervals
(CIs). For multivariate analyses, linear multiple
and logistic regressions were used to identify
independent determinants associated with
HIV RNA detectability in the vagina or plasma.
Multivariate ORs (95% CI) of HIV RNA
genital/plasma detectability were computed
after adjusting for confounding factors. Excess
risks were measured using the risk difference
method.
All tests were two-sided and p<0.05 was
considered significant. Data were analysed
using SPSS® statistical software version 21.0
(SPSS Inc., Chicago, USA).

Detectability of HIV RNA
In both plasma and vagina
Only in plasma
No detectability in plasma
and vagina

5

Results
The median age of the 60 women enrolled in
the study was 30 years (range 18 - 46). All were
black Africans.
Plasma HIV RNA was detected in 42 (70%)
patients. The mean duration on HAART
was 4.2 (±1.6) months for patients with
detectable plasma HIV RNA (CD4+ T-cell
count <350 cells/µl) while for the remaining
18 patients (CD4+ T-cell count ≥350 cells/µl)
it was 10.7 (±1.4) months (p<0.0001).
Of the 42 women with detectable plasma HIV
RNA, 12 (28.6%) had detectable genital HIV
RNA. Only one patient had detectable genital

The univariate analysis (Table 2) showed a
significant association between symptomatic
VVC and plasma HIV RNA detect
ability
(p=0.006), and patients who complained of
symptoms suggestive of symptomatic VVC
had significantly increased plasma HIV RNA
levels (p=0.039). In addition, a recent history
(within the past 3 months) of STIs (p=0.035)
and patients age <35 years (p=0.018) were
also significantly associated with detectable
HIV RNA in the plasma. Furthermore,
the presence of both advanced and severe
HIV-associated immunosupression was
sig
nificantly asso
ciated with HIV RNA
detectability in the plasma (p<0.0001). In
contrast, no patient with a CD4+ T-cell count

6

Plasma HIV RNA (log10 copies/ml)

Statistical analyses

HIV RNA in the absence of detectable plasma
HIV RNA. Plasma HIV RNA levels ranged
from 2.5 (±0.8) log10 copies/ml to 4.1 (±0.8)
log10 copies/ml. Genital HIV RNA levels ranged
from 1.4 log10 copies/ml to 2.5 (±1.1) log10
copies/ml (Table 1). Eight patients out of 12
(66.7%) with detectable genital HIV RNA had
plasma HIV loads >10 000 copies/ ml, while
the remaining patients had plasma HIV loads
of between 20 and 9 999 copies/ ml. Fig. 1
shows the distribution of plasma HIV loads
and genital HIV RNA detectability according
to duration of HAART.
All patients were on HAART regimen 1,
namely two NRTIs and one NNRTI. No
patient received PIs.

4
n=8/21
3

n=13/21

2

n=4/21 n=17/21

n=1/18

1
1 - 3 months

4 - 9 months
Duration of HAART groups

n=17/18

≥10 months

Fig. 1. Distribution of plasma HIV loads and genital HIV RNA detectability among HAART recipients
(n=60). (HAART = highly active antiretroviral therapy.)

Table 1. HIV RNA levels in plasma and GT by HAART duration (N=60)
HAART duration (months)

Patient groups (n)

VL in plasma (log10 copies/ml),
mean (±SD)*

VL in vagina (log10 copies/ml),
mean (±SD)*

0-3

1A (n=8/21)

4.1 (±0.8)

2.5 (±1.1)

1B (n=13/21)

3.3 (±1.4)

<1.3 (not detectable)

2A (n=4/21)

2.5 (±0.9)

1.6 (±0.5)

2B (n=17/21)

2.9 (±1.1)

<1.3 (not detectable)

3A (n=1/18)

<1.3 (not detectable)

1.4

3B (n=17/18)

<1.3 (not detectable)

<1.3 (not detectable)

4-9
≥10

GT = genital tract; HAART = highly active antiretroviral therapy; VL = viral load; SD = standard deviation.
*ANOVA p-value, p<0.0001.
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described previously to detect Mycoplasma
genitalium, Trichomonas vaginalis and herpes
simplex virus type 2.[26,27]
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Table 2. Univariate analysis of factors associated with plasma HIV
RNA levels in HIV-positive women receiving HAART (N=60)
Detectable plasma
HIV RNA, n (%)

Associated factors
Age groups (years)

p-value
0.018

18 - 24

11 (84.6)

25 - 34

25 (75.8)

≥35

6 (42.9)

Symptomatic VVC
(OR 6.1, 95% CI 1.5 - 24.1)

0.006

Yes

23 (88.5)

No

19 (55.9)

Presenting complaints
(OR 5.7, 95% CI 0.9 - 34.7)

0.039

Group 1 (vulval itching, soreness
and discharge)

40 (74.1)

Group 2 (lower abdominal pain, vaginal
discharge)

2 (33.3)

Recent history (past 3 months) of STIs

0.035

Vaginal discharge syndrome

26 (78.8)

Genital ulcer syndrome

6 (85.7)

No STI diagnosed

10 (50.0)

CD4+ T-cell count (cells/µl)

<0.0001

<200

22 (100)

200 - 349

20 (100)

≥350

0 (0)

Genital HIV load categories (copies/ml)

0.062

≥10 000

2 (100)

20 - 9 999

10 (90.0)

<20

30 (65.2)

Genital absolute neutrophil counts

0.095

>20 cells/5 HMFs

12 (60.0)

11 - 20 cells/5 HMFs

13 (92.9)

1 - 10 cells/5 HMFs

17 (65.4)

HAART = highly active antiretroviral therapy; VVC = vulvovaginal candidiasis; OR = odds ratio;
CI = confidence interval; STIs = sexually transmitted infections; HMFs = high microscopic fields.

≥350 cells/µl had detectable plasma HIV
RNA.
In the multivariate analysis (Table 3), logistic
regression was used to identify independent
determinants of HIV RNA levels in plasma
after adjusting for univariate confounding
factors (presenting complaints and recent
history of STIs). CD4+ T-cell counts were
not included in the logistic regression model
because all patients with detectable plasma
HIV RNA had either advanced or severe
immunosupression.
Multivariate analysis showed that a cur
rent episode of symptomatic VVC was inde
pendently (p=0.008) associated with detectable
HIV RNA in the plasma. It was also found that
HIV-infected women aged <35 years were
more likely to have higher HIV RNA levels
in their plasma than women aged ≥35 years
(p=0.039) (Table 3).

Factors associated with
genital HIV RNA shedding
Of the 42 women with detectable plasma HIV
RNA, 12 (28.6%) had detectable levels of HIV
RNA in cell-free vaginal fluid.
Table 4 shows univariate factors associated
with genital HIV RNA detectability among
the patients. Women with a recent history
of vaginal discharge syndrome (p=0.05) and
genital ulcer syndrome (p=0.038) were more
likely to have detectable HIV RNA in their
GTs (Table 4). However, the data showed no
association between gonococcus, VVC or BV
and genital HIV shedding.
Women with a neutrophil cell count score
of >1 had a five-fold higher risk (OR 5.3, 95%
CI 1.6 - 17.2; p=0.004) of having detectable
HIV RNA in their GTs than women with
a neutrophil cell count score of 1. A recent
history of use of broad-spectrum antimicrobial
agents was shown to be associated with

Table 3. Independent determinants of plasma HIV RNA levels in HIV-infected women receiving HAART*(N=60)
Independent variables

β-coefficient

Standard error

Wald χ2

OR (95% CI)

p-value

18 - 24

2.328

1.043

4.978

10.3 (1.3 - 79.2)

0.026

25 - 34

1.765

0.789

5.001

5.8 (1.2 - 27.5)

0.025

Reference

1

6.943

8 (1.7 - 37.7)

Reference

1

Age groups (years)

0.039

≥35
Symptomatic VVC
Yes

2.082

0.790

–1.236

0.719

No
Constant

2.954

HAART = highly active antiretroviral therapy; OR = odds ratio; CI = confidence interval; VVC = vulvovaginal candidiasis.
*Adjusted for presenting complaints and recent history of sexually transmitted infections.
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0.008
0.086

Vaginal HIV RNA detectability (%)

44.8%
38.1%

12.1%

Score (1 - 10/5 HMFs) Score 2 (11 - 20/5 HMFs) Score 3 (>20/5 HMFs)
PMN cells (average actual counts/5 HMFs)

Fig. 2. Distribution of vaginal HIV RNA detectability by PMN cell groups (p=0.005). (PMN=polymorphonuclear
neutrophil; HMFs = high microscopic fields.)

Partial regression plot
Dependent variable: CVL RNA (log10)

3

CVL RNA (log10)

2

1

0

Discussion
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A

−1

0
1
2
Plasma RNA (log10)

3

4

Partial regression plot
Dependent variable: CVL RNA (log10)

3

CVL RNA (log10)

2

1

0

−1

B

detectable HIV shedding in the univariate
analysis (p=0.048) (Table 4).
In the multivariate analysis, after adjusting
for the presence of univariate confounding
factors (use of broad-spectrum antibiotics
and recent history of STIs), an increase in the
vaginal absolute neutrophil counts (p=0.007)
and plasma HIV RNA levels (p=0.032)
remained independently associated with
genital HIV shedding (p=0.005) (Table 5;
Fig. 3). Plasma VL (20 - 9 999 copies/ml)
tended to correlate positively with genital HIV
shedding, but this correlation did not reach
statistical significance (p=0.166). However,
plasma HIV RNA levels ≥10 000 copies/ml
(p=0.032) were independently associated with
genital HIV RNA detectability to a detection
limit of 20 copies/ml (Table 5).
Furthermore, when using transformed
log10 HIV RNA values, correlations between
plasma HIV RNA levels and genital PMN cell
counts >10 cells/5 HMFs with detectability of
genital HIV RNA shedding showed significant
associations (Fig. 3). Detectability and levels
of mean log10 HIV RNA in the vaginal fluid
increased with the increase of plasma HIV
RNA levels (log10) (r=0.2, R2=0.04; p=0.032)
(Fig. 3A) and increased absolute counts of
genital PMN cells (r=0.21, R2=0.045; p=0.007)
(Fig. 3B).

−4

−2

0
2
PMN cells category

4

6

Fig. 3. Variation of genital HIV RNA levels as predicted by (A) plasma HIV loads (r=0.2, R2=0.04; p=0.032) and (B)
genital PMN cells (r=0.21, R2=0.045; p=0.007). (CVL = cervicovaginal lavage; PMN = polymorphonuclear
neutrophil.)

Inflammation of the GT during LGTIs,
particularly STIs and BV, has been reported
to predict increased plasma VLs in HIVinfected women.[28,29] In this study, given that
the majority of women had just initiated
HAART (and therefore had a high rate of
detectable plasma HIV RNA and low CD4+
counts), there was insufficient evidence to
demonstrate that VVC was predictive of high
plasma HIV RNA levels. Although cause and
effect was difficult to unravel in the current
study design, it seemed more likely that the
observed higher level of immunosuppression
among the study participants influenced the
occurrence of VVC. In addition, plasma HIV
loads and local genital inflammation were
predictors of genital HIV shedding, but did
not predict the presence of VVC. Women aged
<35 years were more likely to have increased
plasma HIV RNA levels than women aged
≥35 years. A previous study of the relationship
between age and plasma VL in HIV-infected
individuals showed that older ages (>50 years)
compared with individuals aged 18 - 39 years
were associated with lower levels of HIV-1
replication.[30] This finding was independent of
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antiretroviral therapy use, regimen adherence
and disease stage. One possible explanation
of the relationship between the plasma VL

and age category would be immunological
differences. It has been shown that older age
was associated with an increase in peripheral

Table 4. Univariate analysis of factors associated with genital HIV
RNA detectability in HIV-infected women receiving HAART (N=60)
Associated factors

Detectable
genital HIV
RNA n (%)

OR (95% CI)

p-value

0.7 (0.3 - 2.1)

0.554

0.8 (0.2 - 2.9)

0.781

1.2 (0.3 - 5.3)

0.796

0.5 (0.1 - 4.1)

0.478

0.7 (0.6 - 0.8)

0.183

1.2 (0.5 - 3.2)

0.649

1.2 (0.4 - 4.3)

0.747

Current STIs
Trichomonas vaginalis
Positive

6 (25.0)

Negative

18 (31.6)

Chlamydia trachomatis
Positive

4 (26.7)

Negative

20 (30.3)

Neisseria gonorrhoeae
Positive

3 (33.3)

Negative

21 (29.2)

Mycoplasma genitalium
Positive

1 (16.7)

Negative

23 (30.7)

Herpes simplex virus type 2
Positive

0 (0)

Negative

24 (31.2)

Other lower GT infections
VVC
Infection

13 (32.5)

Colonisation

12 (27.9)

BV
Positive

21 (30.9)

Negative

4 (26.7)

Recent history (past 3 months) of
STIs
Vaginal discharge syndrome

14 (36.8)

3.2 (1.0 - 10.1)

0.050

Genital ulcer syndrome

6 (46.2)

4.6 (1.1 - 19.7)

0.038

No STI

5 (15.6)

1

Genital absolute neutrophil counts

5.3 (1.6 - 17.2)

Score >1

21 (42.0)

Score = 1

4 (12.1)

Plasma HIV RNA levels

0.004

<0.0001

≥10 000 copies/ml (≥4 log10)

8 (100)

20 - 9 999 copies/ml (1.3 log10 3.99 log10)

4 (11.8)

<20 copies/ml (<1.3 log10)

1 (5.6)

Antibiotic use

3.2 (1.01 - 10.60)

Yes

21 (36.8)

No

4 (15.4)

0.048

HAART = highly active antiretroviral therapy; OR = odds ratio; CI = confidence interval; STIs = sexually transmitted infections;
GT = genital tract; VVC = vulvovaginal candidiasis; BV = bacterial vaginosis.
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CD4+ and CD8+ T lymphocytes and that thy
mic involution was associated with this effect,
leading to lower expression of plasma HIV-1
RNA.[30]
Studies of the association between HIV VL
in the female GT and in the plasma have
shown conflicting results. In this study, 28.6%
of the patients shed HIV in their genital
secretions. This finding is consistent with pre
vious reports of HIV-1 DNA and/or RNA
being detected in the GT of 28 - 60% of HIV1-seropositive women.[29,31-33] These previous
studies also demonstrated that genital HIV-1
was more likely to be detected from either the
cell-associated fraction of the cervicovaginal
fluid or whole genital fluid than from cellfree vaginal fluid.[29,31-33] Although within the
published range, our finding of a relatively
low frequency of viraemia in the GT of our
study population may be attributed to the type
of sample that was analysed (measurement
of HIV loads in cell-free fraction alone). It is
difficult to conclude that antiretroviral therapy
significantly lowered HIV RNA levels in genital
secretions, given the fact that the women had
just started HAART.
We found that women with a recent history
of vaginal discharge syndrome and genital
ulcer syndrome were more likely to shed HIV
in their GTs than women without a recent
history of such STIs. However, after testing
for the most common causes of LGTIs, none
of the tested aetiological agents of vaginal
discharge syndrome (VDS) showed significant
association with genital HIV shedding.
The fact that HIV VL was only measured
from the cell-free fraction of genital secretions
may account for the lack of an association
between GT viraemia and tested causes of
VDS, including symptomatic VVC.
We identified two independent factors asso
ciated with HIV RNA shedding in the vagina;
of these factors, one had been previous
ly
identi
fied, namely the associa
tion between
higher levels of plasma HIV RNA and the
ability to detect HIV in genital secretions.[31,34]
Consistent with previous studies, we found
that genital HIV RNA detectability strongly
correlated with plasma HIV VL, but that these
correlations were weak, except when plasma
HIV VL was ≥10 000 copies/ml. Other studies
have suggested that compartmentalisation of
the vaginal immune response from systemic
immunity may account for such weak
correlations.[35,36] This might also be explained
by the fact that HIV VL was only measured
from the cell-free fraction of the genital
secretions.
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Table 5. Independent determinants of HIV RNA detectability in GT of HIV-infected women receiving HAART*
(N=60)
β-coefficient

Standard error

Wald χ2

OR (95% CI)

p-value

≥10 000

2.062

0.962

4.593

7.9 (1.2 - 51.8)

0.032

20 - 9 999

1.168

0.843

0.166

Independent variables
Plasma HIV RNA
(copies/ml)

<20

1.918

3.2 (0.6 - 16.8)

Reference

1

7.308

5.8 (1.6 - 20.8)

Reference

1

Vaginal PMN cells
Score >1

1.758

0.650

Score = 1
Constant

–1.123

0.518

2.980

0.007
0.005

GT = genital tract; HAART = highly active antiretroviral therapy; OR = odds ratio; CI = confidence interval; PMN = polymorphonuclear neutrophil.
*Adjusted for HAART, ATB use and previous STIs.

We also found that the absolute neutrophil count in the genital
mucosa was another factor associated with genital HIV RNA shed
ding. Previous studies have shown the role of genital inflammation in
HIV-1 shedding.[8,37] It has been reported that following HIV-1 infection,
cytokines and chemokines are produced by infected leukocytes
that attract more target cells for HIV-1 infection and allow further
stimulation of the expression of HIV-1 via toll-like receptors.[8-10] In this
study, we found that the number of neutrophils in the female GT was
associated with HIV shedding. Of particular interest, our study did not
show an association between symptomatic VVC and HIV shedding in
the vagina. In addition to the fact that HIV was quantified only in the
cell-free fraction of genital fluids, this lack of association could also be
the result of strong recruitment of neutrophils in the vagina – various
immunomodulators have been reported as associated with the antiCandida activity of neutrophils.[35,36] Cytokines such as TNF-α and IL-8
increase the activity of neutrophils against Candida albicans.[35] Gumbi
et al.[36] reported that women who were detectably shedding HIV-1 in
the GT had significantly increased cervical levels of TNF-α, IL-1β, IL-6
and IL-8 compared with women who were not detectably shedding
the virus. It remains unclear from our observations whether or not
symptomatic VVC is more likely to occur among HIV-infected women
who are not detectably shedding the virus.
Another possible reason why symptomatic VVC was not associated
with genital HIV shedding could be the challenges associated with the
diagnosis of VVC. A clinical definition of VVC could be problematic
even when microscopic tests and cultures of genital samples are used
to support the clinical diagnosis. While Gram staining has a sensitivity
of 75% in supporting the clinical diagnosis of VVC, up to 30% of
women with significant chronic symptoms suggestive of VVC may have
negative cultures at presentation.[38]

Limitations
Limitations of this study include its cross-sectional design and small
sample size. In addition, the impact of factors such as HAART regimen
composition, adherence to HAART and effects of HIV disease stages
were not explored.
The majority of our patients had just started HAART. Therefore, it
is difficult to say that they were not successfully treated. A plausible
hypothesis for why we did not find an association between VVC and
genital HIV shedding could have been the fact that HIV RNA was

only measured from the cell-free fraction of cervicovaginal secretions.
If both HIV complementary DNA and HIV RNA had been measured,
results could have been different. This might also explain why plasma
HIV loads <10 000 copies/ml were not significantly associated with
genital HIV shedding in the multivariate logistic analysis.
Finally, findings present insufficient evidence of the true impact of
VVC on HIV RNA levels in plasma and genital secretions.

Conclusions
Identified factors associated with HIV RNA loads in plasma and female
genital secretions were consistent with previously published factors
from the literature. Of particular note, our study did not have enough
evidence to demonstrate that symptomatic VVC was predictive of
higher levels of HIV RNA in plasma and genital secretions. However,
unlike STIs and BV, symptomatic VVC was less likely to occur among
HIV-infected women who were detectably shedding the virus in
their lower GT, possibly owing to the observed strong recruitment
of neutrophils that possess anti-Candida activity or the challenges
associated with the diagnosis of VVC. About 70% of the study
population had detectable HIV RNA in their plasma; this finding was
supported by the fact that all these patients had a CD4+ T-cell count
<350 cells/µl, which is a marker of systemic immunosuppression. It is
highly likely that the observed higher rate of HIV RNA detectability
was purely the result of immunosuppression and that the associated
high prevalence of symptomatic VVC could have been a consequence
of overall immunosuppression. Further studies are required to
ascertain the impact of VVC on HIV RNA levels in plasma and genital
secretions.
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